WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression. by Ayana E. Morales (17756335)

“…Corresponding densitometry analysis is noted as protein fold expression compared to GAPDH for WT1, p<0.001(***), vFLIP(ns), LANA p<0.05(*), pAKT p<0.05(*), and BCL2 p <0.05(*) using two-sided, unpaired student t-tests. …”

Fig 7 - by Henning Carstens (13132801)

TREM1 inhibition decreases HIV mediated inflammatory cytokine production. by Jinhee Hyun (6900683)

HPx1 expression is controlled by dietary heme and the E75 transcription factor. by Octavio A. C. Talyuli (4285141)

Subjects:

Number of significantly significant (P < 0.05) differentially abundant (SSDA) proteins showing increased or decreased activity (fold change +/- 1.5-fold) relative to time 0 following storage at 9°C or 20°C of infective juveniles of <i>S</i>.... by Peter E. Lillis (12368582)

“…<p>Number of significantly significant (P < 0.05) differentially abundant (SSDA) proteins showing increased or decreased activity (fold change +/- 1.5-fold) relative to time 0 following storage at 9°C or 20°C of infective juveniles of <i>S</i>. …”

Three Ca_V3.3 variants left-shift the window current, while the A398V completely abolishes the window current. by Yousra El Ghaleb (22075892)

Subjects:

5-fold cross-validation comparison results. by Chunming Wen (17616274)

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases V1V2-specific IgG concentration and breadth. by LaTonya D. Williams (3140490)

Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

“…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC_{(tofacitinib, 0–∞)} and a 9.61-fold increase of colonic AUC_{(tofacitinib, 0–12h)}, compared with tofacitinib at a molar equivalent oral dose. …”

GSK343 treatment decreased <i>in vivo</i> tumor volume and growth. by Laura V. Bownes (10276762)

DnaK’s ATPase activity is stimulated by ribosomes and required to reduce protein synthesis. by Carissa Chan (18310140)

DnaK inhibits protein synthesis in vivo and in vitro. by Carissa Chan (18310140)

Preparations of DnaK protein are pure. by Carissa Chan (18310140)

DnaK does not refold heat-denatured luciferase when incubated in the presence of ribosomes. by Carissa Chan (18310140)

Catalytic fold of WT PARG1 C1-GAP domain for RhoA interaction. by Zen Kouchi (14898435)

TBEV infection decrease levels of 18S and 28S rRNA but not 5S rRNA. by Martin Selinger (3195987)

ROC analysis for differentiating bladder cancer patients from controls using the ucfDNA concentration before and after normalization by creatinine concentration in those samples wi... by Meihui Chen (1670020)

Subjects:

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Distribution of miRs with a greater than two fold-change. by Stephanie L. Samani (17896610)

Subjects:

S5 Raw image - by Zhi Xuan Low (19270163)

“…Furthermore, the inclusion complex exhibited reduced systemic toxicity, including reduced inflammation in vital organs as examined by hematoxylin and eosin (H&E) staining. This study also revealed a notable sequential reduction in serum levels of tumour markers, including carcinoembryonic antigen (CEA) and mouse Cytochrome P450 1A2 (CYP1A2), correlating with a significant decrease in tumour bulk volume upon treatment commencement. …”